Rapimig (zolmitriptan) dispersible tablets 5 mg. №2

Description

Rapimig (zolmitriptan) dispersible tablets 5 mg. №2

Composition

active substance: zolmitriptan;

1 tablet contains zolmitriptan 2.5 or 5 mg;

excipients: mannitol E 421, calcium silicate, microcrystalline cellulose, aspartame, sodium starch glycolate (type A), crospovidone (type B), Orange flavor, silicon dioxide colloidal anhydrous, magnesium stearate.

Medicinal form

Orodispersible tablets.

Main physicochemical properties: white, round, flat tablets with a chamfer.

Pharmacotherapeutic group

Means used for migraine. Selective agonists of 5HT1-receptors of serotonin. Zolmitriptan.
ATX code N02C C03.

Pharmacological properties

The drug causes vasoconstriction of cranial vessels, and also inhibits the release of neuropeptides, which are the main effector transmitter of reflex excitement, activates vasodilation, which provokes the onset of a migraine attack. The drug inhibits the development of a migraine attack, without exerting a direct analgesic effect. In addition to stopping a migraine attack, taking the drug eliminates nausea, vomiting associated with left-sided attacks, as well as photo and phonophobia. The drug soothes migraine attacks that occur during menstruation.

Indications

The drug Rapimig dispersible tablets is used to eliminate migraine attacks, which are accompanied by the appearance of an aura or without it.

Contraindications

The appointment of Rapimig is contraindicated in patients with intolerance to zolmitriptan.
Also, its use is contraindicated in severe or moderate arterial hypertension, myocardial infarction, coronary heart disease, angiospastic form of angina pectoris, peripheral vascular disease, cerebrovascular disorders and transient ischemic attacks.

Application during pregnancy and lactation

During pregnancy, the use of Rapimig is justified only if the expected therapeutic effect for the mother significantly outweighs the possible risk to the fetus.

After taking Rapimig, it is possible to resume breastfeeding no earlier than 24 hours later.

Method of administration and dosage

Rapimig dispersible tablets is not used to prevent migraine attacks. The drug is recommended to be used at the first signs of the disease, but its effectiveness is not related to how long after the onset of the attack the pill was taken.

When taking the drug, the tablet can simply be swallowed or put on the tongue and slowly dissolve.

To stop the attack, you need to take one tablet at a dosage of 2.5 mg. If taking the first pill did not allow obtaining the desired effect, then it is recommended to take the drug again within 24 hours. If the use of the second dose is necessary, then it should be taken no earlier than two hours after the first. With a low efficacy of the drug in the minimum dosage, a single dose of the drug at a dosage of 5 mg is permissible. The highest daily dose is 10 mg.

Overdose

When Rapimig dispersible tablets is taken in high doses, the development of a sedative effect is observed.
To eliminate the undesirable effect, the patient undergoes gastric lavage, prescribes the intake of activated carbon and symptomatic treatment.

Side effects

Tachycardia, increased blood pressure, angina pectoris, coronary spasm, sensory disturbances, headache, hyperesthesia, drowsiness, fever, dyspeptic disorders, dry mouth, polyuria, frequent urination, urgency, muscle weakness, asthenia, muscle pain and allergic reactions.